Abstract
Thanks to the introduction of checkpoint inhibitors, patients with classical Hodgkin lymphoma have a better chance at living longer with the disease. However, treatment-related side effects can impact quality of life in the short- and long-term. Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD, provided strategies for preventing and mitigating these adverse events.
